Effects of PCSK9 inhibitors on metabolic-associated fatty liver disease: a short review

Metabolic-associated fatty liver disease (MAFLD), previously known as non-alcoholic fatty liver disease, is a significant epidemiological problem and a well-known cardiovascular risk factor. The increasing number of cases creates the need for new therapeutic methods aimed at improving patient outcom...

Descripción completa

Detalles Bibliográficos
Autores principales: Jakielska, Ewelina, Głuszak, Paweł, Walczak, Marta, Bryl, Wiesław
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2023
Materias:
Review Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10395066/
https://www.ncbi.nlm.nih.gov/pubmed/37538291
http://dx.doi.org/10.5114/pg.2023.126054

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10395066/
https://www.ncbi.nlm.nih.gov/pubmed/37538291
http://dx.doi.org/10.5114/pg.2023.126054

Ejemplares similares